ENO2 and cardiac hypertrophy: Intraperitoneal injection of AAV9 vector containing hFXN transgene expressed under CB (CMV enhancer/chicken beta-actin) promoter increased the life span of NSE-Cre mice by 3-fold and MCK-Cre by 2.7 fold, improved locomotion in NSE-Cre mice, and reduced cardiac hypertrophy and improved the overall cardiac function in MCK-Cre mice (Gérard et al., 2014).